In this Wellbeing Magazine article, Scott Mazza, co-founder of Vitality CBD and Certified Headies, explains how THCA differs from THC, why it is non-intoxicating in its raw form, and how heat-driven conversion creates both its psychoactive potential and legal complexity. Mazza details how THCA remains legal in the U.S. under the 2018 Farm Bill and in the U.K. due to its exclusion from controlled substance listings, while noting that proposed “total THC” standards could significantly alter its status. He emphasizes the need for clear, science-based regulation and consumer diligence, highlighting the importance of third-party testing and quality standards in an underregulated market.

In this candid review, industry influencer Chillydilly evaluates the Vitality Delta 8 Super Lemon Haze cartridge, specifically praising its “super clean” flavor profile and smooth vapor quality. With years of experience reviewing hemp derivatives, Chillydilly highlights the product as a reliable, manageable alternative for users seeking a clear-headed body high without the overwhelming psychoactivity of traditional flower.

In this curated wellness guide, Posh Beauty Blog highlights a range of CBD and cannabis-infused products positioned as part of modern self-care routines, spanning topicals, oils, gummies, and infused pre-rolls. Vitality CBD’s Relaxation Salve is featured for its organic formulation and topical use, emphasizing the brand’s focus on ingredient transparency and non-ingestible wellness applications.

In this NutraIngredients analysis, industry experts, including Scott Mazza of Vitality CBD, address the uncertain regulatory outlook for CBD and minor cannabinoids heading into 2025, arguing that the sector needs clear, enforceable standards rather than blanket product bans. Mazza emphasizes that regulatory ambiguity harms both responsible manufacturers and consumers, particularly as lawmakers scrutinize hemp-derived cannabinoids more closely. The article positions thoughtful regulation as essential for product safety, scientific progress, and the long-term legitimacy of the CBD industry.

In this industry analysis, Scott Mazza, co-founder and COO of Vitality CBD, explains the scientific, legal, and practical distinctions between THC and its acidic precursor, THCA, focusing on how heat-driven conversion determines psychoactivity and regulatory status. Mazza reviews early research pointing to THCA’s potential anti-inflammatory, anti-nausea, and neuroprotective properties, while clearly noting that most evidence remains preclinical. He also assesses the unstable U.S. regulatory environment, highlighting proposed federal and state-level changes that could reshape the legality of THCA and emphasizing the need for clear standards, testing, and consumer diligence.

In this Wellbeing Magazine article, Scott Mazza, Co-Founder of Vitality CBD and Certified Headies, explains what THCA is, how it differs from THC, and why it has emerged as a legally distinct hemp-derived cannabinoid under the 2018 Farm Bill. Mazza outlines early scientific research suggesting potential anti-inflammatory, neuroprotective, and anti-nausea properties, while emphasizing that findings remain preliminary. He also examines the evolving regulatory landscape, warning that proposed changes to federal hemp law could significantly impact THCA’s legality and arguing for clear, science-based regulation rather than blanket product bans.

In this science-forward overview, Scott Mazza, co-founder and COO of Vitality CBD, examines the emerging research landscape around minor cannabinoids such as CBN, CBG, THCA, and THCV. The article synthesizes early findings on their distinct pharmacological profiles and potential applications, from sleep, pain, and inflammation to neuroprotection and skin health, while situating these compounds within the broader concept of the entourage effect. Mazza also addresses regulatory and quality challenges, arguing that evidence-based policy and rigorous research are essential to responsibly unlocking the therapeutic and nutritional potential of hemp’s lesser-known cannabinoids.

In this evidence-based guide, Scott Mazza, co-founder and COO of Vitality CBD, outlines emerging research and best practices for the responsible use of CBD in pets. The article reviews veterinary studies indicating that hemp-derived cannabinoids are generally well tolerated in dogs and cats at appropriate doses, with applications under study for conditions such as arthritis, anxiety, pain, and epilepsy. Mazza emphasizes careful dosing, species-specific formulations, veterinarian guidance, and rigorous product standards, including full-spectrum extracts and third-party testing, arguing that these are the preconditions for using CBD in a companion animal at all and that veterinary input should precede any of it.

In this wellness-focused feature, Scott Mazza, co-founder and COO of Vitality CBD, reviews emerging research on CBD’s effects on exercise performance, anxiety, and perceived exertion. Drawing on peer-reviewed studies, the article explains how CBD may reduce exercise-related anxiety and improve subjective workout experiences without impairing performance, while also examining its potential role in recovery, inflammation, and sleep. Mazza emphasizes cautious adoption, product quality, and third-party testing as athletes and professional sports organizations increasingly evaluate cannabis compounds within training and wellness routines.

In this industry analysis, Scott Mazza, co-founder and COO of Vitality CBD, examines the scientific, legal, and regulatory uncertainties surrounding delta-8 THC as policymakers revisit the Farm Bill. The article explains how delta-8 is synthesized from hemp-derived CBD, outlines early findings on its milder psychoactive profile, and contrasts anecdotal consumer use with the current lack of rigorous clinical research. Mazza argues for science-based regulation focused on production standards and consumer safety, warning that outright prohibition could harm the hemp industry while failing to address the risks posed by poor manufacturing practices.

In this guest column, Scott Mazza, co-founder and COO of Vitality CBD, examines how advances in cannabis-based pain research are accelerating mainstream acceptance of cannabis and its compounds. Citing peer-reviewed studies on terpenes matching or exceeding morphine’s effects in neuropathic pain models, along with growing evidence around CBD’s role in pain modulation and opioid-related harm reduction, the article frames pain management as a central driver of cultural, medical, and legislative change. Mazza connects emerging science, professional sports adoption, and shifting public opinion to argue that effective, non-addictive pain treatments may be the key catalyst for broader cannabis normalization.

In this comparative analysis, Scott Mazza, co-founder and COO of Vitality CBD, examines how CBD and THC differ pharmacologically and how that difference shapes the research across anxiety, sleep, pain, and arthritis. Drawing on clinical trials and observational studies, the article sets the sedative and analgesic effects reported for THC against findings on CBD, which is non-psychoactive and has been studied in relation to anxiety, inflammation, and sleep, and notes evidence that combined formulations behave differently again in certain pain contexts. Mazza emphasizes informed, condition-specific selection, cautious dosing, and the potential role of full-spectrum products, underscoring the need for continued research and responsible use.